(Q53606604)

16 May 2018

title

Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. (English)

1 reference

16 May 2018

1 reference

10

M Hummel

1 reference

16 May 2018

author name string

H Horn

1

1 reference

16 May 2018

M Ziepert

2

1 reference

16 May 2018

M Wartenberg

3

1 reference

16 May 2018

A M Staiger

4

1 reference

16 May 2018

T F E Barth

5

1 reference

16 May 2018

H-W Bernd

6

1 reference

16 May 2018

A C Feller

7

1 reference

16 May 2018

W Klapper

8

1 reference

16 May 2018

C Stuhlmann-Laeisz

9

1 reference

16 May 2018

H Stein

11

1 reference

16 May 2018

D Lenze

12

1 reference

16 May 2018

S Hartmann

13

1 reference

16 May 2018

M-L Hansmann

14

1 reference

16 May 2018

P Möller

15

1 reference

16 May 2018

S Cogliatti

16

1 reference

16 May 2018

M Pfreundschuh

17

1 reference

16 May 2018

L Trümper

18

1 reference

16 May 2018

M Loeffler

19

1 reference

16 May 2018

B Glass

20

1 reference

16 May 2018

N Schmitz

21

1 reference

16 May 2018

G Ott

22

1 reference

16 May 2018

A Rosenwald

23

1 reference

16 May 2018

DSHNHL16

24

1 reference

16 May 2018

publication date

17 February 2015

1 reference

16 May 2018

published in

Leukemia

1 reference

16 May 2018

volume

29

1 reference

16 May 2018

issue

7

1 reference

16 May 2018

page(s)

1564-1570

1 reference

16 May 2018

https://scigraph.springernature.com/pub.10.1038/leu.2015.43

exact match

0 references

cites work

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Numerical and structural genomic aberrations are reliably detectable in tissue microarrays of formalin-fixed paraffin-embedded tumor samples by fluorescence in-situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Measuring nominal scale agreement among many raters

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Genetic aberrations in paediatric acute leukaemias and implications for management of patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Pediatric follicular lymphoma--a clinico-pathological study of a population-based series of patients treated within the Non-Hodgkin's Lymphoma--Berlin-Frankfurt-Munster (NHL-BFM) multicenter trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2015.43

Improving survival and preventing recurrence of diffuse large B-cell lymphoma in younger patients: current strategies and future directions

21 January 2018

1 reference

12 December 2020

Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B-cell lymphomas

1 reference

12 December 2020

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

1 reference

12 December 2020

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.43

1 reference

16 May 2018

Dimensions Publication ID

1044683199

0 references

Fatcat ID

release_dplgmwjop5hllk3sjezrhv4j6y

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/dplgmwjop5hllk3sjezrhv4j6y

24 November 2022

mapped directly with Wikidata item

PubMed ID

25687653

1 reference

16 May 2018